Abstract
The fixed dose combination of telmisartan and amlodipine is indicated for the treatment of arterial hypertension. It includes two antihypertensive agents with different but synergistic mechanisms of action and has a very long half-life that allows once daily dosing to achieve a very good blood pressure control during the night and early morning hours.
The antihypertensive effect was well demonstrated by a number of controlled clinical trials. The fixed combination of telmisartan and amlodipine is well tolerated and the incidence of adverse effects is low, usually lower as compared to single component drugs.
Similarly, the rate of patients who have to discontinue combination therapy due to side effects is about as low as that in placebo patients. The fixed dose combination is available in a relatively wide selection of dose combinations that offer tailored treatment options to patients in whom amlodipine alone fails to provide adequate blood pressure control as well as to patients already receiving telmisartan and amlodipine as monotherapies who will benefit from improved adherence to treatment